$60M RTP startup aims to redefine treatment of severe neuropsychiatric, neurological disorders

A biotechnology startup – soon to be housed in Research Triangle Park – has launched with $60 million in funding and the aim of finding an effective therapy for treatment-resistant depression and other debilitating neuropsychiatric disorders.